Prostate Cancer Consortium Partners with Tech Company Tempus for Trial Examining DNA Abnormalities

Prostate Cancer Consortium Partners with Tech Company Tempus for Trial Examining DNA Abnormalities
The Prostate Cancer Clinical Trials Consortium (PCCTC) has partnered with technology company Tempus to advance its Phase 2 clinical trial to identify the most effective treatment for prostate cancer in patients with genomic evidence of DNA repair problems. Tempus will screen the genomes of potential participants and analyze data from the study. The trial (NCT03012321) is a randomized, Phase 2 study evaluating Lynparza (olaparib) plus prednisone, Zytiga (abiraterone acetate), or a combination of Lynparza, Zytiga, and prednisone in people with metastatic castration-resistant prostate cancer (mCRPC) with DNA repair limitations. Participants with mutations of the three genes ATM, BRCA1, or BRCA2, which are DNA repair pathways thought to be involved in breast cancer and prostate cancer, will be randomized to one of three study groups. The study will enroll 400 patients in more than 20 participating centers. Its primary goal is to determine the time to progression-free survival in each of the treatment groups. “While progress has been made to improve the prognosis of those diagnosed with prostate cancer, castration-resistant prostate cancer is a particularly difficult type to treat,” Maha Hussain, MD, the study’s principal investigator and PCCTC member from Northwestern University’s Robert H. Lurie Comprehensive Cancer Center, said in a 
Subscribe or to access all post and page content.